recurrent prostate cancer

by University of California, Los Angeles edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes Credit: cottonbro studio from Pexels Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease worsening compared with those who received SBRT alone, according […]